Recently, Crimean Congo Hemorrhagic Fever cases have been increasing and the World Health Organization (WHO) announces  the CCHF infections as the second-most risky pathogen following COVID-19. Assessing the antiviral activities of new agents and  designing treatment strategies are of the priorities to tackle the disease. Assoc. Prof. Mert Kuşkucu presented the team’s recent findings on efficiency of various antiviral agents against CCHF in ECCMID which was in Barcelona, Spain on 27-30 April.

KUISCID, with BSL-3 based research of CCHF aims to be one of the pioneers for developing strategies against the disease and our stuıdies will go on.